Related Experiment Video
Updated: Mar 5, 2026
12:01
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
11.4K
The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease.
Naomi P Visanji1, Brit Mollenhauer2, Thomas G Beach3
1Morton & Gloria Shulman Movement Disorders Centre & Edmund J Saffra program in Parkinson's disease, Toronto Western Hospital, 399 Bathurst Street, MCl 7, Toronto, Ontario, M5T 2S8, Canada.
Biomarkers in Medicine
|March 30, 2017
Summary
Researchers are seeking a Parkinson
Area of Science:
- Neuroscience and Neurology
- Biomarker Discovery
Background:
- Parkinson's disease (PD) diagnosis lacks a definitive biomarker.
- Peripheral alpha-synuclein (aSyn) shows potential but lacks reproducibility.
- Existing studies often examine aSyn in limited sample types or patient groups.
Purpose of the Study:
- To identify a reproducible diagnostic and progression biomarker for PD.
- To evaluate alpha-synuclein (aSyn) across multiple tissues and biofluids.
- To understand the evolution of peripheral aSyn throughout the PD disease spectrum.
Main Methods:
- The Systemic Synuclein Sampling Study (S4) evaluates aSyn in various sample types from the same PD subjects.
- Analysis spans the full spectrum of Parkinson's disease.
- Correlates systemic aSyn profiles with dopaminergic function.
Main Results:
- Study is designed to identify optimal biomarker sources and track aSyn evolution.
- Aims to provide vital information on peripheral aSyn changes in PD.
- Will correlate biomarker profiles with nigrostriatal dopaminergic function.
Conclusions:
- This study aims to establish a reliable peripheral biomarker for Parkinson's disease.
- Findings will advance understanding of PD pathophysiology and progression.
- The S4 study is uniquely designed for biomarker reproducibility.
